{"id":"e4f0e8d214e2","type":"article","url":"https://hartvaat.nl/2025/01/13/nt-probnp-en-af-risico-systematische-review-en-meta-analyse/","title":"NT-proBNP en AF-risico: systematische review en meta-analyse","title_en":"Association between NT-proBNP levels and risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog","huisarts"],"tags":["abelacimab","biomarkers-cardiovasculair","nt-probnp"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2024-324685","source_url":"https://doi.org/10.1136/heartjnl-2024-324685","authors":["Wanyue Wang","Tao Zhou","Jinyue Li","Chenxi Yuan","Chenyang Li","Shufeng Chen","Chong Shen","Dongfeng Gu","Xiangfeng Lu","Fangchao Liu"],"significance":6,"published":"2025-01-13","source_date":"2025-01-13","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/screenen-op-af/"],"congress":"","summary_en":"This meta-analysis confirmed the strong association between NT-proBNP levels and AF risk, supporting natriuretic peptide measurement as a pre-screening tool for targeted arrhythmia surveillance.","created":"2026-07-03T10:31:25Z","updated":"2026-07-03T13:30:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Meta-analyse bevestigde het sterke verband tussen NT-proBNP-niveaus en het risico op atriumfibrilleren. De biomarker kan de selectie voor AF-screening verbeteren.","abstract_original":"BACKGROUND AND AIMS: N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a well-established biomarker in clinical practice, particularly for heart failure, but its role in predicting atrial fibrillation (AF) risk is not fully understood. This meta-analysis aimed to evaluate the association between NT-proBNP levels and AF incidence, and to explore the potential of NT-proBNP in enhancing AF risk prediction models. METHODS: We systematically searched databases (PubMed, Embase, Cochrane Library, Web of Science and Scopus) up to August 2024 for prospective studies that reported associations between baseline NT-proBNP levels and incident AF. HRs or relative risks (RRs) with 95% CIs were pooled using random-effects models. RESULTS: This analysis included 136 089 participants from 16 cohorts, with 8017 incident AF cases. Elevated NT-proBNP levels were associated with a higher risk of developing AF (top vs bottom quartile, RR=3.84, 95% CI 3.03 to 4.87; per SD increment, RR=1.70, 95% CI 1.54 to 1.88). A significant non-linear dose-response relationship was observed (Pnon-linearity<0.05), and stronger associations were noted in older populations and when serum samples were used. Adding NT-proBNP to traditional AF risk models improved predictive accuracy, suggesting its value in AF risk stratification. CONCLUSIONS: NT-proBNP levels are strongly associated with an increased risk of AF, particularly in older adults. Incorporating NT-proBNP into risk prediction models may enhance early identification of individuals at risk of AF, with potential implications for population-based screening. PROSPERO REGISTRATION NUMBER: CRD42024538714."}